Development of purified antibodies that kill virus infected cells. This proposal will develop panels of purified and monoclonal antibodies that kill virus infected cells. These antibodies may show efficacy in preventing HIV infection. This is new technology that could subsequently be harnessed to protect or limit the devastating effects of chronic viruses such as HIV.
Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in t ....Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in the past 10 years. This project will evaluate the effectiveness of a new adjuvant as a first step towards the development of a vaccine to target these important infections.Read moreRead less
Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow u ....Novel lipid-based adjuvants for induction of mucosal immunity. The project will determine if needle-free oral and transcutaneous immunisation using LipoVax, a novel lipid-based antigen delivery system developed by the industry partner, can protect mice against the mucosal pathogens Chlamydia and Helicobacter. We expect to show that this immunisation method can induce protective mucosal immunity against two of the most common infectious organisms affecting mankind. If successful this will allow us to develop LipoVax as a new platform technology that can be applied to the development of human vaccines, veterinary vaccines, vaccines for companion animals and vaccines to target infections in feral animals and native wildlife population populations.Read moreRead less
Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This ....Foreign DNA is a danger signal for mammalian cells. This project investigates how cells normally respond to foreign DNA, and is relevant to understanding how the body fights infections, particularly by viruses. The results will help us to design more effective treatments for infectious disease. Studying responses to DNA will also promote the design of new treatments for the autoimmune disease lupus, and help improve technologies or treatments where DNA is introduced into cells or tissues. This includes gene therapy, new strategies for vaccination, and the production of proteins as drugs by biotechnology. The project will promote National Research Priorities in the areas of preventative healthcare, ageing well ageing productively, breakthrough science and new technologies.Read moreRead less
Antimicrobial peptides and immunological protection in a developing mammal. This project offers the opportunity to deliver both economic and scientific benefits, both in the isolation of novel antimicrobials and in positioning Australia's native fauna as important, unique biomedical research models. Antimicrobial peptides offer a solution to the current pressing problem of microbial resistance to antibiotics. This project seeks to isolate such compounds from a previously uninvestigated source, u ....Antimicrobial peptides and immunological protection in a developing mammal. This project offers the opportunity to deliver both economic and scientific benefits, both in the isolation of novel antimicrobials and in positioning Australia's native fauna as important, unique biomedical research models. Antimicrobial peptides offer a solution to the current pressing problem of microbial resistance to antibiotics. This project seeks to isolate such compounds from a previously uninvestigated source, unique to Australia. This project will provide a new perspective on the role of innate protection in a developing mammal, with possible human applications.Read moreRead less
Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
Central nervous system cytokines and morphine analgesia. Morphine remains the drug of choice for the management of moderate-to-severe pain, however its clinical effectiveness is compromised by the fact that morphine's analgesic (pain reducing) efficacy becomes less effective the more it is administered.. This project will examine how analgesic tolerance develops from a completely new approach: Namely, how stimulation of the immune system within the central nervous system is a crucial factor in t ....Central nervous system cytokines and morphine analgesia. Morphine remains the drug of choice for the management of moderate-to-severe pain, however its clinical effectiveness is compromised by the fact that morphine's analgesic (pain reducing) efficacy becomes less effective the more it is administered.. This project will examine how analgesic tolerance develops from a completely new approach: Namely, how stimulation of the immune system within the central nervous system is a crucial factor in the development of tolerance. Modulation of analgesia by the immune system has not been systematically studied and provides a potentially fertile ground for the development of new techniques in the management of clinical pain.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0883081
Funder
Australian Research Council
Funding Amount
$350,000.00
Summary
High Content Cell Signaling Discovery and Screening Facility. The national benefits of this facility will be an increase in basic knowledge of how cells transmit signals to determine their behaviour in normal or stressed situations. There will be high impact publications in learned journals, new IP developed, enhanced education and training in cutting edge technologies. The discoveries from this work will provide candidates for development by the Biotechnology industry in Australia. All of this ....High Content Cell Signaling Discovery and Screening Facility. The national benefits of this facility will be an increase in basic knowledge of how cells transmit signals to determine their behaviour in normal or stressed situations. There will be high impact publications in learned journals, new IP developed, enhanced education and training in cutting edge technologies. The discoveries from this work will provide candidates for development by the Biotechnology industry in Australia. All of this will promote an innovation culture and economy. The work done in this facility addresses several National Research Priority areas including Promoting and maintaining good health, Frontier technologies for transforming industry and Safeguarding Australia.Read moreRead less
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less
Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less